The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.
growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene abeparvovec), wet AMD therapy Lucentis (ranibizumab) and multiple sclerosis drug Kesimpta (ofatumumab).
That includes its wet AMD drug Lucentis (ranibizumab), which fell 25% to bring in $401m in the quarter.
aflibercept) squaring off against Novartis’ older drug Lucentis (ranibizumab), the first VEGF inhibitor for wet AMD to reach the market. ... Novartis’ sales of Lucentis managed a slight gain overall in 2019 to just over $2bn, but fell slightly in the
Lucentis was the first VEGF inhibitor to reach the market for wet AMD and grew quickly into a blockbuster product with sales of around $3.7bn last year. ... Alteogen and Momenta/Mylan have versions of Eylea in development, while Coherus and Xbrane Pharma
The green light for Beovu (brolucizumab) is a boost for Novartis as it tries to defend its wet AMD franchise, currently represented by $2bn-plus VEGF inhibitor product Lucentis (ranibizumab) which ... That compares to four to eight week dosing with
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...